Xin‐Min Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xin‐Min Li has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
David Keegan
Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
2 shared publicationsHaiyun Xu
Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, Saskatoon, Canada
2 shared publicationsRudy Bowen
Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
2 shared publicationsHaitao Wang
Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
1 shared publicationJennifer Chlan‐Fourney
Neuropsychiatry Research Unit, Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
1 shared publicationJue He
Neuropsychiatry Research Unit, Department of Psychiatry, College of Medicine, University of Saskatchewan, Saskatoon, Canada
1 shared publication
Latest Publications
- 1 May 2006
- Published by Wiley in Hippocampus
- Vol. 16 (6) , 551-559
Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress‐induced decrease in cell proliferation and BDNF expression in rat hippocampus
Clinical studies show better response rates of patients with depression and schizophrenia to combinations of atypical antipsychotics and antidepressants, compared to responses to either type of drugs alone. Animal studies demonstrate that some antipsychotics and antidepressants increase neurogenesis and BDNF expression in the hippocampus, which is reduced in volume in patients with depression or schizophrenia. We hypothesized that the better therapeutic effects of combined treatment seen in schizophrenia and depression patients are related to the additive or synergistic effects of combined treatment on hippocampal neurogenesis and BDNF expression. To test this hypothesis, we investigated the effects of chronic administration of quetiapine, venlafaxine, and their combination, on hippocampal cell proliferation and BDNF expression in rats, when subjected to chronic restraint stress (CRS) during the last 2 weeks of a 3‐week drug administration period. We found (1) CRS decreased hippocampal cell proliferation and BDNF expression; (2) chronic administration of quetiapine or venlafaxine dose‐dependently prevented these decreases in hippocampal cell proliferation and BDNF expression caused by CRS (6 h/day for 14days); (3) the combination of lower doses of quetiapine (5mg/kg) and venlafaxine (2.5mg/kg) increased hippocampal cell proliferation and prevented BDNF decrease in stressed rats, whereas each of the drugs exerted mild or no effects; (4) individual higher doses of quetiapine (10mg/kg) or venlafaxine (5mg/kg) exerted effects comparable to those produced by their combination. These results support our hypothesis and can lead to future studies to develop new therapeutic approaches for treatment‐resistant depression and the negative symptoms of schizophrenia.
- 1 May 2006
- Published by Wiley in Hippocampus
- Vol. 16 (6) , 551-559
Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress‐induced decrease in cell proliferation and BDNF expression in rat hippocampus
Clinical studies show better response rates of patients with depression and schizophrenia to combinations of atypical antipsychotics and antidepressants, compared to responses to either type of drugs alone. Animal studies demonstrate that some antipsychotics and antidepressants increase neurogenesis and BDNF expression in the hippocampus, which is reduced in volume in patients with depression or schizophrenia. We hypothesized that the better therapeutic effects of combined treatment seen in schizophrenia and depression patients are related to the additive or synergistic effects of combined treatment on hippocampal neurogenesis and BDNF expression. To test this hypothesis, we investigated the effects of chronic administration of quetiapine, venlafaxine, and their combination, on hippocampal cell proliferation and BDNF expression in rats, when subjected to chronic restraint stress (CRS) during the last 2 weeks of a 3‐week drug administration period. We found (1) CRS decreased hippocampal cell proliferation and BDNF expression; (2) chronic administration of quetiapine or venlafaxine dose‐dependently prevented these decreases in hippocampal cell proliferation and BDNF expression caused by CRS (6 h/day for 14days); (3) the combination of lower doses of quetiapine (5mg/kg) and venlafaxine (2.5mg/kg) increased hippocampal cell proliferation and prevented BDNF decrease in stressed rats, whereas each of the drugs exerted mild or no effects; (4) individual higher doses of quetiapine (10mg/kg) or venlafaxine (5mg/kg) exerted effects comparable to those produced by their combination. These results support our hypothesis and can lead to future studies to develop new therapeutic approaches for treatment‐resistant depression and the negative symptoms of schizophrenia.
- 9 June 2005
- Published by Wiley in Journal of Neuroscience Research
- Vol. 81 (4) , 572-580
Olanzapine and quetiapine protect PC12 cells from β-amyloid peptide25-35-induced oxidative stress and the ensuing apoptosis
We previously found that the atypical antipsychotic drugs (APDs) clozapine, olanzapine, quetiapine, and risperidone reduce PC12 cell death induced by hydrogen peroxide, N‐methyl‐4‐phenylpyridinium ion, or β‐amyloid peptide (Aβ25–35). Such neurotoxic substances have in common the capability of causing oxidative stress. Atypical APDs have been used in treating schizophrenia and in treating psychotic symptoms of patients with Alzheimer's disease (AD), in which Aβ is involved by causing oxidative stress. Therefore, we hypothesized that atypical APDs might alleviate oxidative stress in PC12 cells, thus protecting them from apoptosis. PC12 cells were seeded in plates or chambers for 24 hr and cultured for another 24 hr with olanzapine or quetiapine in the medium, and then the cells were cultured in the new medium containing Aβ25–35 and/or olanzapine, quetiapine, but not serum, for various periods. It was shown that cultures treated with olanzapine + Aβ25–35, or quetiapine + Aβ25–35, had significantly higher cell viabilities and lower rates of apoptosis compared with the cultures exposed only to Aβ25–35. In addition, the drugs blocked the activation of caspase‐3 caused by Aβ25–35. Furthermore, olanzapine and quetiapine prevented Aβ25–35‐induced overproduction of intracellular reactive oxygen species, Aβ25–35‐induced decrease in mitochondrial membrane potential, and Aβ25–35‐induced changes in activities of the key antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase. In consideration of the wealth of evidence linking oxidative stress to the pathophysiology of schizophrenia and AD, these findings give us a new insight into the therapeutic actions of atypical antipsychotics in patients with the disorders.
- 9 June 2005
- Published by Wiley in Journal of Neuroscience Research
- Vol. 81 (4) , 572-580
Olanzapine and quetiapine protect PC12 cells from β-amyloid peptide25-35-induced oxidative stress and the ensuing apoptosis
We previously found that the atypical antipsychotic drugs (APDs) clozapine, olanzapine, quetiapine, and risperidone reduce PC12 cell death induced by hydrogen peroxide, N‐methyl‐4‐phenylpyridinium ion, or β‐amyloid peptide (Aβ25–35). Such neurotoxic substances have in common the capability of causing oxidative stress. Atypical APDs have been used in treating schizophrenia and in treating psychotic symptoms of patients with Alzheimer's disease (AD), in which Aβ is involved by causing oxidative stress. Therefore, we hypothesized that atypical APDs might alleviate oxidative stress in PC12 cells, thus protecting them from apoptosis. PC12 cells were seeded in plates or chambers for 24 hr and cultured for another 24 hr with olanzapine or quetiapine in the medium, and then the cells were cultured in the new medium containing Aβ25–35 and/or olanzapine, quetiapine, but not serum, for various periods. It was shown that cultures treated with olanzapine + Aβ25–35, or quetiapine + Aβ25–35, had significantly higher cell viabilities and lower rates of apoptosis compared with the cultures exposed only to Aβ25–35. In addition, the drugs blocked the activation of caspase‐3 caused by Aβ25–35. Furthermore, olanzapine and quetiapine prevented Aβ25–35‐induced overproduction of intracellular reactive oxygen species, Aβ25–35‐induced decrease in mitochondrial membrane potential, and Aβ25–35‐induced changes in activities of the key antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase. In consideration of the wealth of evidence linking oxidative stress to the pathophysiology of schizophrenia and AD, these findings give us a new insight into the therapeutic actions of atypical antipsychotics in patients with the disorders.
- 1 October 2002
- Published by Wiley in Journal of Neuroscience Research
- Vol. 71 (1) , 127-131
Expression of brain‐derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs
Typical and atypical antipsychotic drugs, though both effective, act on different neurotransmitter receptors and are dissimilar in some clinical effects and side effects. The typical antipsychotic drug haloperidol has been shown to cause a decrease in the expression of brain‐derived neurotrophic factor (BDNF), which plays an important role in neuronal cell survival, differentiation, and neuronal connectivity. However, it is still unknown whether atypical antipsychotic drugs similarly regulate BDNF expression. We examined the effects of chronic (28 days) administration of typical and atypical antipsychotic drugs on BDNF mRNA expression in the rat hippocampus using in situ hybridization. Quantitative analysis revealed that the typical antipsychotic drug haloperidol (1 mg/kg) down‐regulated BDNF mRNA expression in both CA1 (P < 0.05) and dentate gyrus (P < 0.01) regions compared with vehicle control. In contrast, the atypical antipsychotic agents clozapine (10 mg/kg) and olanzapine (2.7 mg/kg) up‐regulated BDNF mRNA expression in CA1, CA3, and dentate gyrus regions of the rat hippocampus compared with their respective controls (P < 0.01). These findings demonstrate that the typical and atypical antipsychotic drugs differentially regulate BDNF mRNA expression in rat hippocampus.
- 1 October 2002
- Published by Wiley in Journal of Neuroscience Research
- Vol. 71 (1) , 127-131
Expression of brain‐derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs
Typical and atypical antipsychotic drugs, though both effective, act on different neurotransmitter receptors and are dissimilar in some clinical effects and side effects. The typical antipsychotic drug haloperidol has been shown to cause a decrease in the expression of brain‐derived neurotrophic factor (BDNF), which plays an important role in neuronal cell survival, differentiation, and neuronal connectivity. However, it is still unknown whether atypical antipsychotic drugs similarly regulate BDNF expression. We examined the effects of chronic (28 days) administration of typical and atypical antipsychotic drugs on BDNF mRNA expression in the rat hippocampus using in situ hybridization. Quantitative analysis revealed that the typical antipsychotic drug haloperidol (1 mg/kg) down‐regulated BDNF mRNA expression in both CA1 (P < 0.05) and dentate gyrus (P < 0.01) regions compared with vehicle control. In contrast, the atypical antipsychotic agents clozapine (10 mg/kg) and olanzapine (2.7 mg/kg) up‐regulated BDNF mRNA expression in CA1, CA3, and dentate gyrus regions of the rat hippocampus compared with their respective controls (P < 0.01). These findings demonstrate that the typical and atypical antipsychotic drugs differentially regulate BDNF mRNA expression in rat hippocampus.
- 24 May 2002
- Published by Wiley in Journal of Neuroscience Research
- Vol. 69 (2) , 278-283
Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal
Atypical antipsychotic drugs are widely used in the treatment of schizophrenia, and clinical evidence has shown that early and prolonged intervention with these drugs will improve the long‐term outcome. It is still unclear, however, whether the atypical antipsychotic drugs are also neuroprotective. To clarify this matter, we used PC12 cell cultures and the MTT assay for cell viability to determine whether various concentrations of the atypical antipsychotics clozapine, quetiapine, and risperidone are neuroprotective after serum withdrawal. In addition, to explore the drugs' actions, Northern blot was used to examine the gene expression of SOD1 (Cu/Zn superoxide dismutase) and p75NTR (p75 neurotrophin receptor). The results demonstrated that 1) the antipsychotic drugs can protect PC12 cells from death after serum withdrawal; cell viability in these drug treatment groups is significantly different from that in the groups without serum in the medium (P < 0.01); and 2) these drugs up‐regulated the SOD1 gene expression to more than 120% (P < 0.05) and also down‐regulated p75NTR mRNA levels to less than 65% of their respective control values (P < 0.05). These findings suggest that the atypical antipsychotics clozapine, quetiapine, and risperidone may exert a neuroprotective function through the modulation of SOD1 and p75NTR expression.
- 24 May 2002
- Published by Wiley in Journal of Neuroscience Research
- Vol. 69 (2) , 278-283
Protective effects of atypical antipsychotic drugs on PC12 cells after serum withdrawal
Atypical antipsychotic drugs are widely used in the treatment of schizophrenia, and clinical evidence has shown that early and prolonged intervention with these drugs will improve the long‐term outcome. It is still unclear, however, whether the atypical antipsychotic drugs are also neuroprotective. To clarify this matter, we used PC12 cell cultures and the MTT assay for cell viability to determine whether various concentrations of the atypical antipsychotics clozapine, quetiapine, and risperidone are neuroprotective after serum withdrawal. In addition, to explore the drugs' actions, Northern blot was used to examine the gene expression of SOD1 (Cu/Zn superoxide dismutase) and p75NTR (p75 neurotrophin receptor). The results demonstrated that 1) the antipsychotic drugs can protect PC12 cells from death after serum withdrawal; cell viability in these drug treatment groups is significantly different from that in the groups without serum in the medium (P < 0.01); and 2) these drugs up‐regulated the SOD1 gene expression to more than 120% (P < 0.05) and also down‐regulated p75NTR mRNA levels to less than 65% of their respective control values (P < 0.05). These findings suggest that the atypical antipsychotics clozapine, quetiapine, and risperidone may exert a neuroprotective function through the modulation of SOD1 and p75NTR expression.